Xbrane Biopharma (Sweden) and Helvetic BioPharma (Switzerland) have signed a sales and distribution agreement to debut Xbrane's biosimilar medicine, Xlucane (Ranibizuma), in Iran. Xlucane is a biosimilar version of Lucentis for the treatment of age-related muscular degeneration. Xbrane estimates the market size for wet AMD in Iran comprises approximately 70,000 patients and constitutes a leading cause of blindness in the country.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.239 SEK | 0.00% |
|
+3.42% | -97.58% |
May. 22 | Xbrane Successfully Scale Up Xdivane- Biosimilar Candidate to Opdivo®? | CI |
May. 16 | Transcript : Xbrane Biopharma AB, Q1 2024 Earnings Call, May 16, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.58% | 34.42M | |
+22.30% | 47.96B | |
+0.83% | 42.45B | |
+43.91% | 41.47B | |
+27.04% | 31.6B | |
+21.26% | 28.63B | |
-4.47% | 28.03B | |
+52.55% | 14.56B | |
+44.78% | 14.14B | |
+3.05% | 12.58B |
- Stock Market
- Equities
- XBRANE Stock
- News Xbrane Biopharma AB
- Xbrane Biopharma and Helvetic Biopharma (Switzerland) Sign a Sales and Distribution Agreement